FR21C1043I2 - Compositions comprenant des benzodiazepines a action breve - Google Patents
Compositions comprenant des benzodiazepines a action breveInfo
- Publication number
- FR21C1043I2 FR21C1043I2 FR21C1043C FR21C1043C FR21C1043I2 FR 21C1043 I2 FR21C1043 I2 FR 21C1043I2 FR 21C1043 C FR21C1043 C FR 21C1043C FR 21C1043 C FR21C1043 C FR 21C1043C FR 21C1043 I2 FR21C1043 I2 FR 21C1043I2
- Authority
- FR
- France
- Prior art keywords
- compositions
- short
- acting benzodiazepines
- benzodiazepines
- acting
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 229940049706 benzodiazepine Drugs 0.000 title 1
- 150000001557 benzodiazepines Chemical class 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
- A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
- C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
- C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
- C07D243/14—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
- C07D243/16—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
- C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
- C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
- C07D243/14—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
- C07D243/16—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals
- C07D243/18—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals substituted in position 2 by nitrogen, oxygen or sulfur atoms
- C07D243/24—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pain & Pain Management (AREA)
- Anesthesiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12168968 | 2012-05-22 | ||
| PCT/EP2013/060543 WO2013174883A1 (en) | 2012-05-22 | 2013-05-22 | Compositions comprising short-acting benzodiazepines |
| EP13730128.9A EP2852389B1 (en) | 2012-05-22 | 2013-05-22 | Compositions comprising short-acting benzodiazepines |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| FR21C1043I1 FR21C1043I1 (enrdf_load_stackoverflow) | 2021-11-19 |
| FR21C1043I2 true FR21C1043I2 (fr) | 2022-10-07 |
Family
ID=48669863
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FR21C1043C Active FR21C1043I2 (fr) | 2012-05-22 | 2021-09-20 | Compositions comprenant des benzodiazepines a action breve |
Country Status (41)
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104059071B (zh) | 2006-07-10 | 2016-06-22 | Paion英国有限公司 | 短效苯并二氮杂*盐及其多晶型 |
| EP2305647A1 (en) | 2009-09-18 | 2011-04-06 | PAION UK Limited | Process for preparing 3-[(4S)-8-bromo-1-methyl-6-(2-pyridinyl)-4 H-imidazo[1,2-a][1,4]benzodiazepine-4-yl] propionic acid methyl ester or the benzene sulfonate salt thereof, and compounds useful in that process |
| EP2450039A1 (en) | 2010-11-08 | 2012-05-09 | PAION UK Ltd. | Dosing regimen for sedation with CNS 7056 (Remimazolam) |
| AR094963A1 (es) | 2013-03-04 | 2015-09-09 | Ono Pharmaceutical Co | Reacción de oxidación excelente en el índice de conversión |
| WO2015076340A1 (ja) * | 2013-11-21 | 2015-05-28 | 小野薬品工業株式会社 | 全身麻酔および／または鎮静のための注射用組成物 |
| EP3106004B1 (en) | 2014-02-10 | 2023-07-19 | Biolumic Limited | Improvements in and relating to controlling characteristics of photosynthetic organisms |
| PL3116296T3 (pl) | 2014-03-14 | 2020-11-16 | Biolumic Limited | Sposób zwiększenia plonowania upraw i/lub odporności na stres |
| HUE047450T2 (hu) | 2014-07-23 | 2020-04-28 | Jiangsu Nhwaluokang Pharmaceutical Res And Development Co Ltd | Új benzodiazepin származék és alkalmazása |
| AU2015318730B2 (en) | 2014-09-17 | 2021-03-25 | Biolumic Limited | Method of seed treatments and resulting products |
| CN105726495B (zh) * | 2014-12-12 | 2019-03-29 | 宜昌人福药业有限责任公司 | 一种注射用短效苯并二氮杂卓盐药物组合物及其制备方法 |
| CN107198691A (zh) * | 2016-03-17 | 2017-09-26 | 江苏恒瑞医药股份有限公司 | 一种瑞马唑仑的药物组合物 |
| ES3027652T3 (en) | 2016-04-14 | 2025-06-16 | Paion Uk Ltd | Orally inhaled and nasal benzodiazepines |
| WO2017198224A1 (zh) * | 2016-05-20 | 2017-11-23 | 江苏恒瑞医药股份有限公司 | 一种瑞马唑仑的药物组合物 |
| EP3500082A1 (en) | 2016-08-22 | 2019-06-26 | Biolumic Limited | System, device and methods of seed treatment |
| CN108503644B (zh) | 2016-12-09 | 2019-06-14 | 成都倍特药业有限公司 | 一种苯并二氮杂*衍生物的氢溴酸盐及其制备方法和用途 |
| AU2018293468A1 (en) | 2017-06-29 | 2020-01-30 | Biolumic Limited | Method to improve crop yield and/or quality |
| EP3714884A1 (en) | 2019-03-27 | 2020-09-30 | Paion UK Limited | Medical uses for benzodiazepines with a particular eeg pattern |
| CN112209932B (zh) * | 2019-07-12 | 2023-03-24 | 成都倍特药业股份有限公司 | 一种化合物氢溴酸盐的新固体形态及其制备方法和用途 |
| ES2803099B2 (es) | 2019-07-22 | 2021-11-08 | Moehs Iberica Sl | Procedimiento de obtención de besilato de remimazolam amorfo |
| CN114478535B (zh) * | 2020-10-23 | 2024-02-09 | 成都苑东生物制药股份有限公司 | 一种苯磺酸瑞马唑仑ii晶型的制备方法 |
| CN112462015B (zh) * | 2020-11-18 | 2022-07-12 | 海南倍特药业有限公司 | 一种氢溴酸瑞马唑仑细菌内毒素的检测方法 |
| CN114624351B (zh) * | 2020-12-14 | 2024-04-09 | 宜昌人福药业有限责任公司 | 苯磺酸瑞马唑仑原料药中(r)-(-)-1-氨基-2-丙醇残留的分析方法 |
| AU2023394304A1 (en) * | 2022-12-16 | 2025-05-22 | Lts Lohmann Therapie-Systeme Ag | Oromucosal delivery system containing remimazolam |
| WO2024251275A1 (zh) * | 2023-06-09 | 2024-12-12 | 成都麻沸散医药科技有限公司 | 一种氮杂*类化合物及其组合物和应用 |
| WO2025052259A1 (en) | 2023-09-05 | 2025-03-13 | Reena Patel | Ready to use compositions of remimazolam |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3520877A (en) * | 1967-10-02 | 1970-07-21 | Hoffmann La Roche | 3-carbonyl amino acetic acid ethyl ester substituted benzodiazepines |
| CA2143246C (en) | 1994-03-16 | 2000-08-22 | Thierry Godel | Imidazodiazepines |
| JP3001979B2 (ja) | 1995-01-06 | 2000-01-24 | エフ・ホフマン−ラ ロシュ アーゲー | ヒドロキシメチル−イミダゾジアゼピン類及びそれらのエステル |
| WO1996023790A1 (de) | 1995-02-02 | 1996-08-08 | F. Hoffmann-La Roche Ag | Acetylimidazobenzodiazepine |
| JPH0971533A (ja) * | 1995-06-30 | 1997-03-18 | Takeda Chem Ind Ltd | 凍結乾燥製剤 |
| US7160880B1 (en) * | 1999-05-14 | 2007-01-09 | Cenes Limited | Short-acting benzodiazepines |
| GB9911152D0 (en) * | 1999-05-14 | 1999-07-14 | Glaxo Group Ltd | Short-acting benzodiazepines |
| TWI233805B (en) * | 1999-07-01 | 2005-06-11 | Fujisawa Pharmaceutical Co | Stabilized pharmaceutical composition in lyophilized form as antifungal agent |
| EP1161949A1 (en) * | 2000-06-09 | 2001-12-12 | Warner-Lambert Company | Use od diazepinoindoles for the treatment of chronic obstructive pulmonary disease |
| EP2332524A1 (en) * | 2005-02-15 | 2011-06-15 | Elan Pharma International Limited | Aerosol and injectable formulations of nanoparticulate benzodiazepine |
| GB0613692D0 (en) * | 2006-07-10 | 2006-08-16 | Cenes Ltd | Benzodiazepine salts |
| GB0613693D0 (en) * | 2006-07-10 | 2006-08-16 | Cenes Ltd | Benzodiazepine salts (3) |
| CN104059071B (zh) * | 2006-07-10 | 2016-06-22 | Paion英国有限公司 | 短效苯并二氮杂*盐及其多晶型 |
| CN101352422B (zh) * | 2008-09-17 | 2011-04-20 | 厦门朝阳生物工程有限公司 | 河豚毒素冻干粉针制剂及其制备方法 |
| HRP20160253T1 (hr) * | 2009-11-05 | 2016-04-08 | Glaxosmithkline Llc | Inhibitor benzodiazepinske bromodomene |
| EP2450039A1 (en) * | 2010-11-08 | 2012-05-09 | PAION UK Ltd. | Dosing regimen for sedation with CNS 7056 (Remimazolam) |
| CN102964349A (zh) | 2011-08-31 | 2013-03-13 | 江苏恒瑞医药股份有限公司 | 苯并二氮杂*衍生物的托西酸盐及其多晶型、它们的制备方法和用途 |
-
2013
- 2013-05-22 RS RS20171260A patent/RS56660B1/sr unknown
- 2013-05-22 SG SG11201407710VA patent/SG11201407710VA/en unknown
- 2013-05-22 PT PT137301289T patent/PT2852389T/pt unknown
- 2013-05-22 CN CN201380036582.2A patent/CN104968348B/zh active Active
- 2013-05-22 AU AU2013265295A patent/AU2013265295B2/en active Active
- 2013-05-22 PL PL13730128T patent/PL2852389T4/pl unknown
- 2013-05-22 SI SI201330840T patent/SI2852389T1/en unknown
- 2013-05-22 TW TW102118175A patent/TWI590826B/zh active
- 2013-05-22 EP EP13730128.9A patent/EP2852389B1/en active Active
- 2013-05-22 PE PE2014002207A patent/PE20150683A1/es active IP Right Grant
- 2013-05-22 JP JP2015513164A patent/JP6313286B2/ja active Active
- 2013-05-22 NO NO13730128A patent/NO2852389T3/no unknown
- 2013-05-22 MY MYPI2014003222A patent/MY185117A/en unknown
- 2013-05-22 MX MX2014014225A patent/MX368854B/es active IP Right Grant
- 2013-05-22 BR BR112014029108-0A patent/BR112014029108B1/pt active IP Right Grant
- 2013-05-22 LT LTEP13730128.9T patent/LT2852389T/lt unknown
- 2013-05-22 HR HRP20171872TT patent/HRP20171872T1/hr unknown
- 2013-05-22 WO PCT/EP2013/060543 patent/WO2013174883A1/en active Application Filing
- 2013-05-22 CN CN201810206738.1A patent/CN108578413A/zh active Pending
- 2013-05-22 AP AP2014008084A patent/AP2014008084A0/xx unknown
- 2013-05-22 DK DK13730128.9T patent/DK2852389T3/en active
- 2013-05-22 MA MA37581A patent/MA37581B1/fr unknown
- 2013-05-22 US US14/402,590 patent/US20150148338A1/en not_active Abandoned
- 2013-05-22 ES ES13730128.9T patent/ES2651389T3/es active Active
- 2013-05-22 AR ARP130101779A patent/AR092008A1/es not_active Application Discontinuation
- 2013-05-22 UA UAA201413655A patent/UA115063C2/uk unknown
- 2013-05-22 KR KR1020147036021A patent/KR102116737B1/ko active Active
- 2013-05-22 CA CA2874247A patent/CA2874247C/en active Active
- 2013-05-22 HU HUE13730128A patent/HUE037734T2/hu unknown
- 2013-05-22 EA EA201492160A patent/EA032119B1/ru unknown
- 2013-05-22 GE GEAP201313666A patent/GEP20186852B/en unknown
- 2013-05-22 NZ NZ702063A patent/NZ702063A/en unknown
-
2014
- 2014-11-18 TN TN2014000479A patent/TN2014000479A1/fr unknown
- 2014-11-18 ZA ZA2014/08412A patent/ZA201408412B/en unknown
- 2014-11-19 IL IL235789A patent/IL235789B/en active IP Right Grant
- 2014-11-21 CL CL2014003171A patent/CL2014003171A1/es unknown
- 2014-11-21 PH PH12014502608A patent/PH12014502608B1/en unknown
- 2014-11-24 CO CO14258220A patent/CO7151503A2/es unknown
- 2014-12-19 EC ECIEPI201432553A patent/ECSP14032553A/es unknown
-
2021
- 2021-08-16 US US17/402,730 patent/US20220040198A1/en not_active Abandoned
- 2021-09-17 LT LTPA2021521C patent/LTPA2021521I1/lt unknown
- 2021-09-20 FR FR21C1043C patent/FR21C1043I2/fr active Active
- 2021-09-20 LU LU00230C patent/LUC00230I2/fr unknown
- 2021-09-20 HU HUS2100040C patent/HUS2100040I1/hu unknown
- 2021-09-20 NO NO2021041C patent/NO2021041I1/no unknown
- 2021-09-21 NL NL301130C patent/NL301130I2/nl unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FR21C1043I2 (fr) | Compositions comprenant des benzodiazepines a action breve | |
| SI3725778T1 (sl) | Formulacije enzalutamida | |
| EP2875051A4 (en) | ANTIBODIES AGAINST SIGLEC-15 | |
| EP2832855A4 (en) | NOVEL ANTI-SIGLEC-15 ANTIBODY | |
| DK2868318T4 (da) | Injicerbar formulering | |
| DK2877155T3 (da) | Opioidformuleringer | |
| GB201302688D0 (en) | Detergent formulation | |
| EP2928903A4 (en) | OLIGONUKLEOTIDREZEPTUR | |
| GB201211247D0 (en) | Improved formulation | |
| UA24206S (uk) | Логотип | |
| UA25270S (uk) | Логотип | |
| UA25183S (uk) | Логотип | |
| UA25311S (uk) | Логотип | |
| UA25098S (uk) | Логотип | |
| UA24011S (uk) | Логотип | |
| UA24400S (uk) | Логотип | |
| UA24392S (uk) | Логотип | |
| UA24393S (uk) | Логотип | |
| UA24394S (uk) | Логотип | |
| UA24390S (uk) | Логотип | |
| UA24389S (uk) | Логотип | |
| UA24388S (uk) | Логотип | |
| UA24387S (uk) | Логотип | |
| UA24386S (uk) | Логотип | |
| UA24699S (uk) | Логотип |